Profile of temsirolimus in the treatment of advanced renal cell carcinoma
نویسندگان
چکیده
منابع مشابه
Profile of temsirolimus in the treatment of advanced renal cell carcinoma
Temsirolimus is a potent inhibtor of the mammalian target of rapamycin (mTOR). In various clinical trials temsirolimus has shown an overall survival benefit for patients with metastatic renal cell carcinoma (mRCC). Thus it is approved for first-line therapy in high-risk mRCC patients. We discuss the indication, side effects and clinical implications of temsirolimus treatment.
متن کاملTemsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
BACKGROUND Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease. METHODS In this multicenter, phase 3 trial, we randomly assigned 626 patients with previously untreated, poor-prognosis metastatic renal-cell carcinoma to...
متن کاملTemsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
Temsirolimus is a targeted therapy that inhibits mammalian target of rapamycin (mTOR), a central regulator of tumor cell responses to growth stimuli. Temsirolimus has a broad anticancer activity profile that impacts tumor cell growth, proliferation, and survival through its specific inhibition of mTOR. In a randomized phase III trial that enrolled previously untreated patients with advanced ren...
متن کاملTreatment of Locally Advanced Renal Cell Carcinoma
Context: Locally advanced renal cell carcinoma (RCC) is associated with a poor prognosis despite radical surgery. The surgical approach can differ according to tumour size, location, and vascular involvement. The development of molecular targeted therapies aroused new interest in adjuvant and neoadjuvant strategies. Objective: The aim of this article was to review trends in surgical approaches ...
متن کاملTemsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.
BACKGROUND Temsirolimus, a novel inhibitor of mammalian target of rapamycin, has demonstrated prolonged overall survival and progression-free survival compared with interferon alfa (IFN) in patients with advanced renal cell carcinoma (RCC) and poor prognostic features. Adverse events (AEs) of any causality were previously reported, but AEs that were deemed temsirolimus related are of particular...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: OncoTargets and Therapy
سال: 2010
ISSN: 1178-6930
DOI: 10.2147/ott.s7657